Page 213 - Read Online

Landi et al. Neuroimmunol Neuroinflammation 2018;5:29 I http://dx.doi.org/10.20517/2347-8659.2018.35 Page 13 of 16

35. Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK. Cancer immu-
notherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl
Med 2017;9:eaan4220.
36. Desjardins A, Sampson JH, Vlahovic G, Peters KB, Randazzo D, Threatt S, Herndon JE, Bullock CA, Miller ES, Boulton S, Lally-Goss
D, McSherry F, Lipp ES, Friedman AH, Friedman HS, Bigner DD, Gromeier M. Dose finding study of the intratumoral administration
of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG). J Clin Oncol 2017;35 suppl
15:e13533.
37. Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD,
Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, Fiveash JB, Gillespie GY. A phase 1 trial of oncolytic HSV-1, G207, given in
combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 2014;22:1048-55.
38. Clements D, Helson E, Gujar SA, Lee PW. Reovirus in cancer therapy: an evidence-based review. Oncolytic Virother 2014;3:69-82.
39. Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson
JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA,
Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington
KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA. Intravenous delivery of oncolytic reovirus to brain tumor patients
immunologically primes for subsequent checkpoint blockade. Sci Transl Med 2018;10:eaam7577.
40. Schirrmacher V. Fifty years of clinical application of newcastle disease virus: time to celebrate! Biomedicines 2016;4:16.
41. Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol 2001;2:REVIEWS1017.
42. Yamashita M, Emerman M. Retroviral infection of non-dividing cells: old and new perspectives. Virology 2006;344:88-93.
43. Richardson AM, Collins SA, Inagaki A, Armstrong VL, Roussel M, Jolly D, Robbins DJ, Ayad N, Kasahara N. PDTM-19. TOCA 511
& TOCA FC: pre-clinical proof of concept in medulloblastoma. Neuro Oncol 2017;19:vi193.
44. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998;80:35-47.
45. George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, Mc-
Guinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM,
Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B gene therapy with a high-specific-activity factor
IX variant. N Engl J Med 2017;377:2215-27.
46. Chiocca EA, Yu J, Phuphanich S, Lukas RV, Kumthekar P, Yang Y, Zhou Q, Buck JY, Deary A, Cai H, Barrett JA, Cooper LJN, Lebel
FM. Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: tolerability and survival in recurrent glioblastoma. J
Clin Oncol 2017;35 suppl 15:2044.
47. Ziopharm. A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG. ClinicalTrials.gov Identifier:
NCT03330197.
48. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu
MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant
trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
49. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med
2000;6:443-6.
50. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of Herceptin resistance
in breast cancer cells. Cytometry A 2004;57:86-93.
51. Fiszman GL, Jasnis MA. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int J Breast Cancer
2011;2011:352182.
52. Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron
2015;8:15-21.
53. Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Va-
japeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE. Efficacy of bevacizumab plus
irinotecan in children with recurrent low-grade gliomas - a pediatric brain tumor consortium study. Neuro Oncol 2014;16:310-7.
54. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma
multiforme. Oncologist 2009;14:1131-8.
55. Qaddoumi I, Kocak M, Pai-Panandiker A, Armstrong G, Wetmore C, Crawford J, Lin T, Boyett J, Kun L, Boop F, Merchant T, Ellison
D, Gajjar A, Broniscer A. Phase II trial of erlotinib during and after radiotherapy in children with newly diagnosed high-grade gliomas.
Front Oncol 2014;4:67.
56. Jakacki RI, Foley MA, Horan J, Wang J, Kieran MW, Bowers DC, Bouffet E, Zacharoulis S, Gill SC. Single-agent erlotinib versus oral
etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. J Neurooncol 2016;129:131-8.
57. Kol A, van Scheltinga AT, Pool M, Gerdes C, de Vries E, de Jong S. ADCC responses and blocking of EGFR-mediated signaling and
cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells. Oncotarget 2017;8:45432-46.
58. Hassan SB, Sørensen JF, Olsen BN, Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clini-
cal trials. Immunopharmacol Immunotoxicol 2014;36:96-104.
59. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19:1035-43.
60. Pediatric Brain Tumor Consortium. Phase I Study of APX005M in Pediatric CNS Tumors. ClinicalTrials.gov Identifier: NCT03389802.
61. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M,
Weissman IL. Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.
Proc Natl Acad Sci U S A 2013;110:11103-8.
62. Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willing-
ham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G, Taylor MD,